S&P 500   3,297.75 (+1.58%)
DOW   27,167.57 (+1.31%)
QQQ   272.17 (+2.55%)
AAPL   112.18 (+3.66%)
MSFT   208.87 (+2.80%)
FB   255.68 (+2.46%)
GOOGL   1,443.73 (+1.47%)
AMZN   3,097.94 (+2.59%)
TSLA   405.04 (+4.45%)
NVDA   513.24 (+3.91%)
BABA   271.03 (+0.48%)
CGC   14.23 (-0.28%)
GE   6.14 (+1.32%)
MU   49.08 (-0.79%)
AMD   78.17 (+3.10%)
T   28.09 (+0.18%)
F   6.54 (-1.80%)
ACB   5.05 (-2.88%)
GILD   62.43 (+0.29%)
NFLX   484.41 (+2.39%)
DIS   123.98 (+1.22%)
BAC   23.51 (+0.73%)
BA   155.21 (+6.27%)
S&P 500   3,297.75 (+1.58%)
DOW   27,167.57 (+1.31%)
QQQ   272.17 (+2.55%)
AAPL   112.18 (+3.66%)
MSFT   208.87 (+2.80%)
FB   255.68 (+2.46%)
GOOGL   1,443.73 (+1.47%)
AMZN   3,097.94 (+2.59%)
TSLA   405.04 (+4.45%)
NVDA   513.24 (+3.91%)
BABA   271.03 (+0.48%)
CGC   14.23 (-0.28%)
GE   6.14 (+1.32%)
MU   49.08 (-0.79%)
AMD   78.17 (+3.10%)
T   28.09 (+0.18%)
F   6.54 (-1.80%)
ACB   5.05 (-2.88%)
GILD   62.43 (+0.29%)
NFLX   484.41 (+2.39%)
DIS   123.98 (+1.22%)
BAC   23.51 (+0.73%)
BA   155.21 (+6.27%)
S&P 500   3,297.75 (+1.58%)
DOW   27,167.57 (+1.31%)
QQQ   272.17 (+2.55%)
AAPL   112.18 (+3.66%)
MSFT   208.87 (+2.80%)
FB   255.68 (+2.46%)
GOOGL   1,443.73 (+1.47%)
AMZN   3,097.94 (+2.59%)
TSLA   405.04 (+4.45%)
NVDA   513.24 (+3.91%)
BABA   271.03 (+0.48%)
CGC   14.23 (-0.28%)
GE   6.14 (+1.32%)
MU   49.08 (-0.79%)
AMD   78.17 (+3.10%)
T   28.09 (+0.18%)
F   6.54 (-1.80%)
ACB   5.05 (-2.88%)
GILD   62.43 (+0.29%)
NFLX   484.41 (+2.39%)
DIS   123.98 (+1.22%)
BAC   23.51 (+0.73%)
BA   155.21 (+6.27%)
S&P 500   3,297.75 (+1.58%)
DOW   27,167.57 (+1.31%)
QQQ   272.17 (+2.55%)
AAPL   112.18 (+3.66%)
MSFT   208.87 (+2.80%)
FB   255.68 (+2.46%)
GOOGL   1,443.73 (+1.47%)
AMZN   3,097.94 (+2.59%)
TSLA   405.04 (+4.45%)
NVDA   513.24 (+3.91%)
BABA   271.03 (+0.48%)
CGC   14.23 (-0.28%)
GE   6.14 (+1.32%)
MU   49.08 (-0.79%)
AMD   78.17 (+3.10%)
T   28.09 (+0.18%)
F   6.54 (-1.80%)
ACB   5.05 (-2.88%)
GILD   62.43 (+0.29%)
NFLX   484.41 (+2.39%)
DIS   123.98 (+1.22%)
BAC   23.51 (+0.73%)
BA   155.21 (+6.27%)
Log in
NASDAQ:TCRR

Tcr2 Therapeutics Stock Forecast, Price & News

$18.40
+0.35 (+1.94 %)
(As of 09/25/2020 02:39 PM ET)
Add
Compare
Today's Range
$18.09
Now: $18.40
$18.42
50-Day Range
$16.74
MA: $18.64
$20.69
52-Week Range
$5.84
Now: $18.40
$20.94
Volume2,052 shs
Average Volume189,255 shs
Market Capitalization$613.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCRR
CUSIPN/A
CIKN/A
Phone617-949-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.68 per share

Profitability

Net Income$-47,600,000.00

Miscellaneous

Employees47
Market Cap$613.53 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$18.40
+0.35 (+1.94 %)
(As of 09/25/2020 02:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tcr2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

How has Tcr2 Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Tcr2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TCRR stock has increased by 114.5% and is now trading at $18.40.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Tcr2 Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tcr2 Therapeutics
.

When is Tcr2 Therapeutics' next earnings date?

Tcr2 Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Tcr2 Therapeutics
.

How were Tcr2 Therapeutics' earnings last quarter?

Tcr2 Therapeutics Inc (NASDAQ:TCRR) posted its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.65) by $0.02.
View Tcr2 Therapeutics' earnings history
.

What price target have analysts set for TCRR?

7 Wall Street analysts have issued twelve-month price objectives for Tcr2 Therapeutics' stock. Their forecasts range from $25.00 to $35.00. On average, they expect Tcr2 Therapeutics' stock price to reach $31.80 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price.
View analysts' price targets for Tcr2 Therapeutics
.

Are investors shorting Tcr2 Therapeutics?

Tcr2 Therapeutics saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 1,440,000 shares, an increase of 9.1% from the July 30th total of 1,320,000 shares. Based on an average trading volume of 322,100 shares, the days-to-cover ratio is currently 4.5 days. Approximately 5.2% of the company's stock are sold short.
View Tcr2 Therapeutics' Short Interest
.

Who are some of Tcr2 Therapeutics' key competitors?

What other stocks do shareholders of Tcr2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tcr2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), II-VI (IIVI), LogicBio Therapeutics (LOGC), Atreca (BCEL) and Sorrento Therapeutics (SRNE).

Who are Tcr2 Therapeutics' key executives?

Tcr2 Therapeutics' management team includes the following people:
  • Dr. Garry E. Menzel, Pres, CEO & Director (Age 55)
  • Mr. Robert Hofmeister, Chief Scientific Officer (Age 52)
  • Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 48)
  • Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 46)

When did Tcr2 Therapeutics IPO?

(TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is Tcr2 Therapeutics' stock symbol?

Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are Tcr2 Therapeutics' major shareholders?

Tcr2 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (4.07%), Artal Group S.A. (1.45%), Granite Point Capital Management L.P. (0.42%), Charles Schwab Investment Management Inc. (0.41%), Nuveen Asset Management LLC (0.24%) and Bank of New York Mellon Corp (0.23%). Company insiders that own Tcr2 Therapeutics stock include Morana Jovan-Embiricos, Neil W Gibson and Upnorth Investment Ltd.
View institutional ownership trends for Tcr2 Therapeutics
.

Which institutional investors are selling Tcr2 Therapeutics stock?

TCRR stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., ArrowMark Colorado Holdings LLC, and UBS Group AG. Company insiders that have sold Tcr2 Therapeutics company stock in the last year include Morana Jovan-Embiricos, and Neil W Gibson.
View insider buying and selling activity for Tcr2 Therapeutics
.

Which institutional investors are buying Tcr2 Therapeutics stock?

TCRR stock was bought by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Nuveen Asset Management LLC, Jacobs Levy Equity Management Inc., California Public Employees Retirement System, GAM Holding AG, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., and Bank of New York Mellon Corp. Company insiders that have bought Tcr2 Therapeutics stock in the last two years include Morana Jovan-Embiricos, and Upnorth Investment Ltd.
View insider buying and selling activity for Tcr2 Therapeutics
.

How do I buy shares of Tcr2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tcr2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $18.40.

How big of a company is Tcr2 Therapeutics?

Tcr2 Therapeutics has a market capitalization of $613.53 million. The company earns $-47,600,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe.

What is Tcr2 Therapeutics' official website?

The official website for Tcr2 Therapeutics is www.tcr2.com.

How can I contact Tcr2 Therapeutics?

Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.